← Back to Search

Radiation

LITT + Radiation for Brain Tumor (GCCC 19140 Trial)

N/A
Recruiting
Research Sponsored by University of Maryland, Baltimore
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age ≥ 22 years old
Patient must have received prior radiation therapy for initial treatment of glioma
Must not have
Infratentorial tumor or evidence of leptomeningeal spread
Patients that are not surgical candidates for stereotactic biopsy or laser ablation
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Summary

This trial is testing a new way to treat patients with brain tumors that have come back. The treatment involves using a laser to heat up and destroy the tumor, and then using radiation to kill any remaining cancer cells.

Who is the study for?
This trial is for adults over 22 with recurrent WHO Grade II-IV gliomas, who've had prior radiation therapy. They must have a tumor ≤ 6 cm, not undergone re-irradiation, and be in good enough health to undergo surgery. Women of childbearing age need a negative pregnancy test and all participants must agree to use contraception.Check my eligibility
What is being tested?
The study tests using Laser Interstitial Thermal Therapy (LITT) followed by Hypo-fractionated Radiation Therapy on patients with recurring brain tumors called gliomas. It aims to see how effective this combination is for treatment after initial therapies have failed.See study design
What are the potential side effects?
Potential side effects may include typical risks associated with surgical procedures like LITT and radiation therapy such as infection, bleeding, neurological damage or deficits, fatigue from radiation, skin irritation at the treatment site, and other organ-specific reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 22 years old or older.
Select...
I have had radiation therapy for my brain tumor before.
Select...
I can care for myself but may need occasional help.
Select...
My brain tumor has come back or gotten worse after treatment.
Select...
It has been at least 8 weeks since my last radiation treatment.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My cancer has spread to the lower part of my brain or its lining.
Select...
I cannot undergo surgery for a stereotactic biopsy or laser ablation.
Select...
I have heart problems that affect my daily activities.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events
Secondary outcome measures
1-year overall survival
Median overall survival
Median progression-free survival
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Experimental: LITT with Hypofractionated radiation therapyExperimental Treatment2 Interventions
Laser interstitial thermal therapy (LITT) followed by hypo-fractionated radiation therapy, 35Gy/10 fractions.

Find a Location

Who is running the clinical trial?

University of Maryland, BaltimoreLead Sponsor
695 Previous Clinical Trials
376,999 Total Patients Enrolled
3 Trials studying Glioblastoma
63 Patients Enrolled for Glioblastoma
Keep Punching FoundationUNKNOWN
1 Previous Clinical Trials
32 Total Patients Enrolled
1 Trials studying Glioblastoma
32 Patients Enrolled for Glioblastoma

Media Library

Hypo-Fractionated Radiation Therapy (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT04181684 — N/A
Glioblastoma Research Study Groups: Experimental: LITT with Hypofractionated radiation therapy
Glioblastoma Clinical Trial 2023: Hypo-Fractionated Radiation Therapy Highlights & Side Effects. Trial Name: NCT04181684 — N/A
Hypo-Fractionated Radiation Therapy (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04181684 — N/A
~7 spots leftby Dec 2025